Cogent Biosciences, Inc.
NASDAQ Global SelectTotal Valuation
Cogent Biosciences, Inc. carries a market capitalization of 5.21B, placing it among publicly traded companies globally. Its enterprise value stands at 6.16B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 5.21B |
| Enterprise Value | 6.16B |
Share Statistics
Cogent Biosciences, Inc. currently has 171.60M shares outstanding.
| Shares Outstanding | 171.60M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 14.20 |
| P/TBV Ratio | 14.20 |
| P/FCF Ratio | -20.06 |
| P/OCF Ratio | -19.95 |
Financial Position
Cogent Biosciences, Inc. maintains a current ratio of 13.57, meaning it holds 13.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 45.88, indicating elevated leverage, while an interest coverage ratio of -74.21 demonstrates limited ability to service its debt obligations.
| Current Ratio | 13.57 |
| Quick Ratio | 13.36 |
| Debt / Equity | 45.88 |
| Debt / EBITDA | -0.64 |
| Interest Coverage | -74.21 |
Financial Efficiency
| Return on Equity (ROE) | -146.55 |
| Return on Assets (ROA) | -68.00 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Cogent Biosciences, Inc.'s stock has gained approximately 85.0185% over the past 52 weeks. The 50-day moving average sits at 33.60, while the 200-day moving average is 35.88.
| Beta (5Y) | N/A |
| 52-Week Price Change | 85.0185% |
| 50-Day Moving Average | 33.60 |
| 200-Day Moving Average | 35.88 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -384.28M, while operating income came in at -389.09M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -389.09M |
| Pretax Income | -377.18M |
| Net Income | -377.18M |
| EBITDA | -384.28M |
| EBIT | -389.09M |
| Earnings Per Share (EPS) | -2.38 |
Balance Sheet
Cogent Biosciences, Inc. holds 792.30M in cash and equivalents against 244.26M in total debt, resulting in a net debt position of 42.29M. Total book value stands at 467.64M, with working capital of 745.52M providing operational flexibility.
| Cash & Cash Equivalents | 792.30M |
| Total Debt | 244.26M |
| Net Debt | 42.29M |
| Equity (Book Value) | 467.64M |
| Book Value Per Share | 2.73 |
| Working Capital | 745.52M |
Cash Flow
Cogent Biosciences, Inc. produced -307.54M in operating cash flow over the past twelve months. After subtracting -1.69M in capital expenditures, free cash flow totaled -309.24M - equivalent to -1.95 per share.
| Operating Cash Flow | -307.54M |
| Capital Expenditures | -1.69M |
| Free Cash Flow | -309.24M |
| FCF Per Share | -1.95 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -12.97 |
| FCF Yield | -4.99 |
Stock Splits
Cogent Biosciences, Inc.'s most recent stock split took place on November 9, 2020 with a 4:1 split ratio.
| Last Split Date | 11/9/2020 |
| Split Ratio | 4:1 |
Scores
Cogent Biosciences, Inc. posts an Altman Z-Score of 10.40, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 10.40 |